Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy symbols : Gnpx save search
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 2.36%
H: 6.6%
C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Published: 2024-04-03 (Crawled : 12:30) - prnewswire.com
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 1.76%
H: 13.15%
C: 7.61%
reqorsa lung cancer treat cell trial therapy study
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
Published: 2024-04-02 (Crawled : 12:30) - prnewswire.com
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: -5.72%
H: 7.14%
C: 1.43%
oncoprex positive system preclinical therapy
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
Published: 2024-03-12 (Crawled : 13:00) - prnewswire.com
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: -1.49%
H: 0.0%
C: -9.07%
reqorsa patent treat grant therapy
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-03-06 (Crawled : 13:30) - prnewswire.com
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 24.27%
H: 5.66%
C: -14.45%
reqorsa lung positive treatment system preclinical meeting therapy
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2024-02-05 (Crawled : 12:30) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.17%
H: 0.09%
C: -2.76%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 33.84%
H: 1.01%
C: -15.3%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.76%
H: 0.77%
C: 0.0%
reqorsa first lung cancer treat cell expansion therapy study
Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"
Published: 2023-10-20 (Crawled : 14:00) - biospace.com/
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: -2.91%
H: 1.67%
C: -0.03%
lung therapy
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
Published: 2023-09-21 (Crawled : 12:30) - globenewswire.com
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: -1.79%
H: 2.27%
C: -2.32%
drug treatment designation therapy
Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer
Published: 2023-08-10 (Crawled : 13:00) - biospace.com/
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 6.25%
H: 1.75%
C: -5.57%
reqorsa fda lung drug granted cancer cell treatment designation therapy
Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate
Published: 2023-07-11 (Crawled : 14:00) - biospace.com/
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 1.25%
H: 3.41%
C: -1.43%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.28%
H: 0.25%
C: -0.23%
fda lung drug candidate cancer cell designation therapy fast track designation
Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers
Published: 2023-07-05 (Crawled : 14:20) - biospace.com/
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 2.08%
H: 1.02%
C: -5.62%
reqorsa patent granted treat chinese therapy
Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer
Published: 2023-06-28 (Crawled : 14:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -2.36%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 14.85%
H: 1.18%
C: -7.27%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.29%
H: 0.13%
C: -0.7%
reqorsa fda lung cancer cell treatment designation therapy fast track designation
Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
Published: 2023-05-25 (Crawled : 21:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: -0.02%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 3.65%
H: 7.04%
C: 1.02%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 1.06%
H: 0.48%
C: -0.04%
reqorsa lung asco positive cancer cell meeting trial therapy
Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System
Published: 2023-05-23 (Crawled : 12:00) - biospace.com/
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: -0.29%
H: 0.29%
C: 0.1%
oncoprex positive system preclinical medical therapy
Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting
Published: 2023-04-19 (Crawled : 13:20) - prnewswire.com
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 15.79%
H: 0.0%
C: -10.0%
oncoprex lung report positive cancer cell system preclinical meeting therapy
Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes
Published: 2023-02-23 (Crawled : 15:00) - biospace.com/
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 7.32%
H: 6.25%
C: -21.02%
diabetes therapy study
Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh
Published: 2022-12-15 (Crawled : 12:20) - prnewswire.com
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 0.86%
H: 5.98%
C: 1.71%
program license technology diabetes therapy
Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers
Published: 2022-08-16 (Crawled : 12:00) - biospace.com/
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 15.31%
H: 10.79%
C: -7.47%
patent therapy
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer
Published: 2022-03-31 (Crawled : 12:00) - biospace.com/
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 1.96%
H: 0.0%
C: -3.62%
keytruda trial therapy cancer enroll phase 1
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2022-03-02 (Crawled : 14:00) - biospace.com/
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 0.37%
H: 2.02%
C: 2.02%
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 3.95%
H: 5.06%
C: -7.17%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
tagrisso gene therapy trial cel lung cancer phase 1 therapy cancer
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.